Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ruxolitinib + methylprednisolone
- Development stage
- Unknown
- Lead developer
- Incyte
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
**Ruxolitinib + methylprednisolone** is a combination therapy of a small-molecule Janus kinase (JAK) inhibitor (ruxolitinib) and a synthetic glucocorticoid corticosteroid (methylprednisolone), investigated as a first-line or salvage regimen for immune-related diseases, especially **acute graft-versus-host disease (aGVHD)** after allogeneic stem cell transplantation and in relapsed/refractory multiple myeloma. - Ruxolitinib acts as a JAK1/JAK2 inhibitor, blocking pro-inflammatory cytokine signaling, thus modulating T-cell and immune responses. - Methylprednisolone is a potent glucocorticoid, suppressing multiple inflammatory and immune pathways by binding the cytosolic glucocorticoid receptor. The combination demonstrates superior response rates and improved immune regulatory cell recovery compared to steroid-only regimens in aGVHD, and shows well-tolerated efficacy as a salvage option in multiple myeloma.
- Other names
- ruxolitinib + corticosteroidslow-dose ruxolitinib plus methylprednisoloneruxolitinib plus methylprednisolone
02
Targets
JAK3 (Janus kinase 3)JAK2 (Janus kinase 2)JAK1 (Janus kinase 1)GR (Glucocorticoid receptor)TYK2 (Tyrosine kinase 2)
Beyond the preview
Go deeper on ruxolitinib + methylprednisolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ruxolitinib + methylprednisolone.